Introduction {#s1}
============

The phosphatidylinositol 3-kinase (PI3K) pathway is a master regulator of many cellular processes. Activation of the class 1A PI3K is gated, in part, by the p85α regulatory subunit, which contains a Src homology 3 (SH3) domain, two proline-rich (PR) regions (PR1 and PR2) separated by a Rho-GAP/BCR-homology (BH) domain, and two Src homology 2 (SH2) domains (nSH2, cSH2) flanking an inter-SH2 (iSH2) domain. The interaction of p85α nSH2-iSH2-cSH2 fragment with the p110 catalytic subunit represses p110 activity allosterically and also stabilizes p110 against degradation, creating a pool of stable but quiescent p110 ([@bib48]). Upon receptor tyrosine kinase activation, p85α undergoes phosphorylation/dephosphorylation events that alleviate p110 inhibition resulting in p110-mediated production of PI(3,4,5)P3 ([@bib10]). Strikingly, *PIK3R1*, the gene coding for p85α, is the twelfth most frequently mutated gene across all cancers. Indeed, somatic mutations of the p85α:p110α interface disrupt the inhibitory action of p85α on bound p110α leading to PI3K pathway activation in cancers ([@bib33]; [@bib20]). However, *PIK3R1* mutations outside the nSH2-iSH2-cSH2 fragment are relatively common in cancers, particularly endometrial cancer. The mechanisms underlying the transforming activity of these mutations remain to be elucidated and may provide novel biomarkers or therapeutic opportunities.

Although the best-characterized role of p85α is p110-dependent, interaction of p85α with other proteins via its SH3 and BH domains has been proposed to mediate p110-independent functions ([@bib22]; [@bib7]). We and others have also shown that the BH domain binds to the tumor suppressor PTEN to promote PTEN protein stability and that at least one *PIK3R1* somatic mutation interferes with this process ([@bib5]; [@bib8]). Moreover, intermolecular interactions between the SH3 domain and the PR region of p85α contribute to p85α homodimerization ([@bib16]; [@bib8]). However, the function of p85α homodimers remains to be elucidated. In this study, we demonstrate that p110α-free p85α homodimers positively regulate PTEN and that this regulatory mechanism is disrupted by mutations in a subset of endometrial cancers. Together, our findings suggest that the relative abundance of p110α-bound p85α monomer and p110α-free p85α homodimer is critical in PI3K pathway regulation.

Results {#s2}
=======

The p85α PR1:SH3 domain interaction contributes to stabilization of the p85α homodimer and PTEN binding, whereas PR2 contributes to PTEN binding but not to homodimer formation {#s2-1}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Previous analyses suggested that the region encompassing SH3-PR1-BH of p85α mediates p85α homodimerization and binding to PTEN ([@bib16]; [@bib5]; [@bib8]). However, how each motif contributes to homodimerization and the orientation of the homodimer remain unknown. Using analytical ultracentrifugation (AUC) and microscale thermophoresis (MST), we demonstrated that purified recombinant full-length p85α homodimerized with a micromolar dissociation constant *K*~*d*~ in absence of other proteins under reducing conditions (*K*~*d*~ was 7 ± 0.7 μM and 3.9 ± 0.2 μM for AUC and MST, respectively) ([Figure 1---figure supplements 1, 2](#fig1s1 fig1s2){ref-type="fig"}). AUC and MST also showed that the SH3-PR1-BH-PR2 fragment retained the full capacity to dimerize (*K*~*d*~ was 0.53 ± 0.03 μM and 0.44 ± 0.03 μM for AUC and MST, respectively). The difference in dimerization *K*~*d*~ between the N-terminal fragment and full-length p85α might indicate an additional entropic penalty arising upon full-length dimerization and/or weak intramolecular interactions occurring between the SH3-PR1-BH-PR2 and the nSH2-iSH2-cSH2 fragments in the monomer, which have to be displaced to allow dimerization.

The isolated SH3 domain does not form stable dimers in size-exclusion chromatography ([@bib16]) and none of the available p85α SH3 crystal structures (\[PDB 3I5S ([@bib2]), 3I5R ([@bib2]), 1PHT ([@bib29]\]) contains quaternary assemblies predicted to be stable in solution by the PISA algorithm ([@bib24]), suggesting that SH3:SH3 contacts do not have a major role in p85α homodimerization. We therefore asked if the p85α homodimer could be stabilized by SH3:PR1 interactions in trans. p85α PR1 (residues 79--99) contains a canonical class I PXXP SH3-interacting motif (\[**R**/**K**\]XX**P**XX**P**; **R**^93^PL**P**^96^VA**P**^99^) ([@bib25]). Indeed, our isothermal titration calorimetry (ITC) analyses showed that the synthetic p85α PR1 peptide PKPRPP**R**PL**P**VA**P** bound purified recombinant p85α SH3 with a *K*~*d*~ of 24 μM ([Figure 1---figure supplement 3M](#fig1s3){ref-type="fig"}). p85α SH3 bound p85αΔSH3 (residues 86--742, comprising PR1 to cSH2) with a similar *K*~*d*~ of 17 μM ([Figure 1---figure supplement 3N](#fig1s3){ref-type="fig"}), demonstrating that the p85α SH3 domain binds PR1 also in the context of an almost complete p85α, in agreement with previously published qualitative data ([@bib16]). The linker between SH3 and PR1 in p85α is too short for an SH3:PR1 interaction to occur in *cis* ([Figure 1---figure supplement 3O](#fig1s3){ref-type="fig"}), indicating that the SH3:PR1 interaction would need to form in *trans* in the p85α homodimer. Two published experimental structures provide comparable templates for this interaction: (i) p85α SH3 in a complex with a class I PXXP peptide that is similar to PR1 (HSK**R**PL**P**PL**P**SL; *K*~*d*~ of 40 μM; \[[@bib2]\]) and (ii) p85α PR1 in a complex with Fyn SH3 (*K*~*d*~ 16 μM) ([@bib37]). We used this structural information to build a theoretical homology model for the SH3:PR1 interaction to guide studies aimed at identifying the amino acids involved in the molecular interactions ([Figure 1A](#fig1){ref-type="fig"}).10.7554/eLife.06866.003Figure 1.Intermolecular interactions contribute to p85α homodimerization and PTEN binding.(**A**) Theoretical molecular model of the p85α SH3:PR1 interaction. The Qualitative Model Energy Analysis (QMEAN) Z-score of the model is −0.8 \[the QMEAN Z-score ranges from −4 (worse) to +4 (best) with the average for high-resolution X-ray structures being 0 ([@bib3])\]. Key residues on the Src homology 3 (SH3) domain (green) are highlighted. The RXXPXXP motif of the PR1 region (carbons colored in amber) is indicated. (**B**) Schematic showing the residues mutated in the PR1 and PR2 mutants. (**C**) KLE cells co-transfected with Flag-tagged wild-type (WT) p85α (Flag-WT) and HA-tagged WT p85α or proline-rich (PR) mutants for 72 hr were harvested for immunoprecipitation (IP) with anti-HA and Western blotting (WB). (**D**, **E**) In other sets of the experiment, cells co-transfected with Flag-WT and mutants in SH3 domain (**D**) or both SH3 and PR domains (**E**) were harvested for IP using the same Materials and methods. (**F**) The molecular structure of BH:BH domain dimer, taken from the crystal structure of this domain (1PBW). Individual monomers are color-coded. P309, the last PR2 residue modeled in the crystal structure, is indicated. The zoom-in window shows details of the BH:BH interaction, with residues discussed in this study highlighted. (**G**) KLE cells co-transfected with Flag-WT and HA-WT or mutants in BH domain were collected for IP with anti-HA. LacZ was used as control. Numerical values below each lane of the immunoblots represent quantification of the relative protein levels by densitometry (normalized to HA levels). (**H**) Schematic model of the p85α SH3-PR1-BH homodimer. The nSH2-iSH2-cSH2 fragment is not included the model.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.003](10.7554/eLife.06866.003)10.7554/eLife.06866.004Figure 1---figure supplement 1.(**A**--**F**) Sedimentation equilibrium data for full-length p85α, p85α PR1-SH3-BH-PR2 (residues 1--333), and p85α PR1-BH (residues 79--301).The data of final equilibrium profiles (black symbols) were fitted (red line) to the monomer--dimer--tertramer model (p85α and p85α PR1-SH3-BH-PR2) or a monomer--dimer model (PR1-BH) with reduced χ^2^ of 1.253, 1.14, and 1.18 and root mean squared differences of 0.0026--0.0090, 0.0021--0.0073, 0.0017--0.0018; yielding the dimerization *K*~*d*~ of 7.0 ± 0.7 μM, 0.53 ± 0.03 μM, and 162.9 ± 41.4 μM for p85α, p85α PR1-SH3-BH-PR2, and p85α PR1-BH, respectively. The errors represent standard errors. (**G**--**I**) Sedimentation coefficient distribution profiles of each protein at 1.5 mg/ml.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.004](10.7554/eLife.06866.004)10.7554/eLife.06866.005Figure 1---figure supplement 2.(**J**--**L**) Microscale thermophoresis (MST) data on dimerization of p85α (full length, SH3-PR1-BH-PR2 and PR1-BH).Affinities for individual constructs were determined at *K*~*d*~ ~p85α~ = 3.9 ± 0.2 μM, *K*~*d*~ ~p85α1-333~ = 441 ± 30 nM, and *K*~*d*~ ~p85α\ PR1-BH~ = 22.3 ± 1.5 μM. The errors are standard deviation calculated from three independent measurements.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.005](10.7554/eLife.06866.005)10.7554/eLife.06866.006Figure 1---figure supplement 3.(**M**--**N**) Isothermal titration calorimetry (ITC) data on p85α SH3:PR1 and p85αΔSH3 interactions.*K*~*d*~ = 23.3 ± 6 μM, ΔG = −26.5 kJ/mol, ΔH = −4.9 kJ/mol, TΔS = 21.5 kJ/mol and the stoichiometry N = 1.06 ± 0.3 (**M**) and *K*~*d*~ = 16.8 ± 4.2 μM ΔG = −27.7 kJ/mol, ΔH = −13.4 kJ/mol, TΔS = 14.4 kJ/mol and the stoichiometry N = 0.8 ± 0.1(**N**). Measurement errors are less than 10% for ΔH and TΔS, as judged from independent analysis of repeat experiments. The errors are standard deviation. (**O**) Graphical illustration showing that SH3:PR1 interactions in cis are not possible because the RXXPXXP motif (color-coded) on PR1 (white) is located too close to the SH3 domain C-terminus to be able to reach the RXXPXXP binding site on the same SH3 (green surface). RXXPXXP bound to SH3 is shown as color-coded spheres.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.006](10.7554/eLife.06866.006)10.7554/eLife.06866.007Figure 1---figure supplement 4.(**A**, **B**) p85α knockout mouse embryonic fibroblast (MEF) cells (A) or PTEN knockout MEF cells (B) co-transfected with Flag-tagged WT p85α (Flag-WT) and HA-tagged WT p85α or PR mutants for 72 hr were collected for IP with anti-HA and WB.(**C**) KLE cells co-transfected with Flag-WT and HA-tagged WT p85α or truncated mutant A360\* were collected for IP with anti-HA and WB. LacZ was used as control. Numerical values below the immunoblots represent quantification of the relative protein levels by densitometry.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.007](10.7554/eLife.06866.007)10.7554/eLife.06866.008Figure 1---figure supplement 5.(**A**) KLE cells co-transfected with HA-tagged WT p85α (or p85β) and Flag-tagged WT p85α (or p85β) for 72 hr were harvested for IP with anti-HA and WB.(**B**) The crystallographic BH domain dimers from p85α (PDB id. 1PBW; light and dark red) and p85β (PDB 2XS6; yellow and pale yellow) are superimposed on one of the BH domains. (**C**) KLE cells transfected with WT p85α or WT p85β for 72 hr were collected for WB. LacZ was used as control.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.008](10.7554/eLife.06866.008)

We mutated either the key prolines or basic residues in the PR1 and PR2 regions proposed to bind p85α SH3 ([Figure 1B](#fig1){ref-type="fig"}). These mutants were expressed in an endometrial cancer cell line KLE, which expresses low level of endogenous p85α and does not have mutations in major members of the PI3K pathway. Co-immunoprecipitation analysis showed that mutations in prolines (denoted as PR1mut) or basic residues (PR1mut\') in PR1 decreased p85α homodimerization ([Figure 1C](#fig1){ref-type="fig"}). Consistent with our hypothesis that homodimerized p85α binds PTEN, PR1mut, and PR1mut\' decreased the association of p85α with PTEN ([Figure 1C](#fig1){ref-type="fig"}). Interestingly, both PR2mut (proline residues mutated) and PR2mut\' (basic residues mutated) decreased binding to PTEN without affecting p85α dimerization ([Figure 1C](#fig1){ref-type="fig"}), suggesting that PR2 contributes directly to PTEN binding rather than to p85α homodimerization. Accordingly, PTEN binding was further decreased by combined mutations of PR1 and PR2 (PR1+PR2mut and PR1+PR2mut\'), which however did not decrease p85α homodimerization compared to PR1 mutations alone. These observations were replicated in p85α knockout mouse embryonic fibroblasts (MEFs) ([Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}) and more importantly in PTEN knockout MEFs ([Figure 1---figure supplement 4B](#fig1s4){ref-type="fig"}), indicating that the p85α homodimer is able to form in the absence of PTEN.

We next mutated p85α SH3 residues predicted to mediate binding to PR1 ([Figure 1A](#fig1){ref-type="fig"}). The D21A/W55A double mutant, which targets the canonical RXXPXXP binding site, decreased p85α homodimerization and PTEN interaction comparably to PR1mut or PR1+PR2mut ([Figure 1D](#fig1){ref-type="fig"}). Mutations of E19 and E20, which situate on the SH3 RT loop and may contribute to long-range electrostatic interactions with PR1 (e.g., K88 and R90), also decreased p85α homodimerization and PTEN binding ([Figure 1D](#fig1){ref-type="fig"}). The D21A/W55A and E19A/E20A mutations further decreased p85α homodimerization and hence PTEN binding when combined with PR1+PR2mut ([Figure 1E](#fig1){ref-type="fig"}). In the p85α SH3:HSK**R**PL**P**PL**P**SL crystal structure (3I5R) ([@bib2]) and our p85α SH3:PR1 model ([Figure 1A](#fig1){ref-type="fig"}), R18 weakly interacts with R93 of the PR1 RXXPXXP motif via a planar stacking interaction. Accordingly, R18A modestly decreased p85α homodimerization ([Figure 1D](#fig1){ref-type="fig"}).

None of these mutants altered the interaction of p85α with p110α ([Figure 1C--E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4A,B](#fig1s4){ref-type="fig"}), consistent with C-terminus but not N-terminus of p85α contributing to p110α binding. The spatial separation of p85α homodimerization from p110α interaction sites is further supported by our observations that a truncation p85α mutant, A360\*, which lacks the nSH2-iSH2-cSH2 fragment to bind p110α, displayed comparable p85α homodimerization and PTEN binding to wild-type (WT) p85α ([Figure 1---figure supplement 4C](#fig1s4){ref-type="fig"}). It is noteworthy that none of the mutations in PR1 disrupted binding to PTEN without affecting p85α homodimerization, consistent with a causal link between homodimerized p85α and PTEN binding. Together, these results suggest that a canonical SH3:PR1 interaction in trans contributes to the formation of the homodimeric p85α platform for PTEN binding, whereas PR2 contributes to binding to PTEN through an alternative mechanism and potentially by direct PTEN binding.

The p85α BH:BH domain interaction contributes to stabilization of the p85α homodimer {#s2-2}
------------------------------------------------------------------------------------

The p85α BH-PR2 fragment (residues 105--319) forms BH:BH domain dimers in two different crystal forms, suggesting that this dimer arrangement is not an artifact of a particular crystallization condition ([@bib34]). The crystallographic dimer is stabilized by M176 that inserts into a hydrophobic pocket formed mainly by L164\', I177\', V181\' ([Figure 1F](#fig1){ref-type="fig"}). The BH:BH interface in the crystal structure is highly conserved in vertebrates. As experimental support for this BH dimer, we found that a M176A mutation decreased p85α homodimerization and PTEN binding ([Figure 1G](#fig1){ref-type="fig"}). In contrast, mutation of D178, which was predicted to contribute to BH:BH dimer formation only minimally in our model ([Figure 1F](#fig1){ref-type="fig"}), did not diminish p85α homodimerization.

In each monomer, the BH:BH association buries only 527 Å^2^ of the total solvent-accessible area of 9000 Å^2^, suggesting that the BH:BH interaction alone is insufficient for stable p85α homodimerization. Indeed, we measured a much lower affinity for p85α PR1-BH (AUC: 163 μM; MST: 23 μM) than for constructs containing the SH3-PR1-BH region ([Figure 1---figure supplements 1C and 2L](#fig1s1 fig1s2){ref-type="fig"}). Together with the decrease in p85α homodimerization that occurred with combined mutations of PR1 and M176 ([Figure 1G](#fig1){ref-type="fig"}), these data support a model wherein the p85α homodimer is stabilized by both SH3:PR1 and BH:BH interactions. The length of the SH3-BH linker is sufficient for SH3:PR1 interactions in trans within the context of the crystal-derived BH:BH dimer ([Appendix figure 3](#fig10){ref-type="fig"} in [Appendix 1](#app1){ref-type="app"}). Collectively, our data are consistent with a molecular model for the p85α homodimer in which the SH3 domain binds PR1 in trans through a canonical class I interaction, while simultaneously the two BH domains associate through an interface centered on M176 ([Figure 1H](#fig1){ref-type="fig"}). The contribution of the BH domain in the homodimerization of p85 appears to be important, because p85β, which has a completely conserved SH3 ligand-binding site, an almost identical sequence in the PR1 motif and an 80% identity in the nSH2-iSH2-cSH2 fragment, homodimerized and interacted with PTEN to a lesser degree than p85α ([Figure 1---figure supplement 5A](#fig1s5){ref-type="fig"}). Indeed, the p85α and p85β BH domains share only 30% identity, and in particular the region that mediates BH dimerization in p85α is not conserved in p85β, neither in sequence nor in the published crystallographic structure (p85α: PDB 1PBW and p85β: PDB 2XS6) ([Figure 1---figure supplement 5B](#fig1s5){ref-type="fig"}).

Disruption of p85α homodimerization is associated with decreased stability of PTEN through ubiquitination {#s2-3}
---------------------------------------------------------------------------------------------------------

Our previous data suggested that p85α homodimerization and PTEN binding contribute to increased PTEN stability by inhibiting ubiquitination ([@bib8]). We therefore investigated whether p85α mutants that alter formation of p85α homodimers and/or PTEN binding affect PTEN ubiquitination and stability. WT p85α markedly decreased PTEN ubiquitination compared with LacZ control and more importantly with each of the homodimer-disrupting mutants (R18A, E19A/E20A, D21A/W55A, and R66A in SH3; PR1mut, PR1mut' in PR1; M176A in BH) and PTEN binding-disrupting mutants (PR2mut and PR2mut\') ([Figure 2A--C](#fig2){ref-type="fig"}). Ubiquitinated PTEN in cells expressing the mutants was less than that in cells expressing LacZ because there was more PTEN-bound homodimer present in the mutant cells. PR1+PR2mut and PR1+PR2mut\' increased ubiquitinated PTEN compared with single mutations, suggesting cooperativity between PR1 and PR2 in preventing PTEN ubiquitination. Further, the increased PTEN ubiquitination in the presence of these mutants was associated with decreased PTEN protein levels and hence activation of the PI3K pathway as indicated by increased AKT phosphorylation ([Figure 2D--F](#fig2){ref-type="fig"}). Conversely, p85β failed to stabilize PTEN, as expected from the reduced dimerization and altered BH domain structure of this isoform ([Figure 1---figure supplement 5C](#fig1s5){ref-type="fig"}).10.7554/eLife.06866.009Figure 2.p85α homodimer increases protein stability, lipid phosphatase activity, and membrane association of PTEN.(**A**--**F**) KLE cells transfected with WT p85α or PR1 and PR2 mutants (**A, D**), SH3 domain mutants (**B, E**), or BH domain mutants (**C, F**) for 72 hr were collected for IP with anti-PTEN and WB with anti-ubiquitin (**A**--**C**) or directly for WB (**D--F**). PTEN protein levels were normalized prior to IP by using proportionally different amounts of lysates. (**G**) In vitro lipid phosphatase activity of recombinant PTEN in the presence or absence of recombinant p85α was determined. (**H**) Endogenous PTEN proteins were immunoprecipitated indirectly using anti-p85α antibody and phosphatase activity was measured. The activity was normalized to the levels of immunoprecipitated PTEN protein in each sample. (**I**) Transfected KLE cells were harvested for subcellular fractionation and WB (C, cytosol; M, membrane; N, nuclear). (**J**) Binding of recombinant PTEN to large multilamellar vesicles in the presence or absence of recombinant p85α was assayed. Pellets (P) and supernatants (S) corresponding to phospholipid-bound fraction and phospholipid-unbound fraction, respectively, were subjected to SDS-PAGE followed by top, Coomassie blue staining or bottom, WB. Numerical values below the immunoblots represent relative protein levels by densitometry. \*p \< 0.05, compared with LacZ control. ^\#^p \< 0.05, compared with WT. The error bars represent S.D. of triplicates from two independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.009](10.7554/eLife.06866.009)10.7554/eLife.06866.010Figure 2---figure supplement 1.(**A**) Negative feedback of the phosphatidylinositol 3-kinase (PI3K) pathway mediated by S6K.(**B**) The efficiency of siRNAs targeting S6K was confirmed by WB. Non-specific (NS) siRNA was used as control. (**C**, **D**) KLE cells co-transfected with WT p85α or PR1+PR2mut and 10 nM siRNA targeting S6K or NS control for 72 hr were harvested for WB directly (**C**) or IP with anti-HA and WB (**D**). (**E**) Positive feedback of the PI3K pathway mediated by mTORC2 to AKT. (**F**) The efficiency of siRNAs targeting Rictor was confirmed by WB. (**G**, **H**) Cells co-transfected with WT p85α or PR1+PR2mut and 10 nM siRNA targeting Rictor or NS control for 72 hr were harvested for WB directly (**G**) or IP with anti-HA (**H**). (**I**) Feedforward activation of mTOR by AKT. (**J**) Cells were treated with rapamycin (500 nM) or AKT inhibitor (MK2206; 1 μM) for 48 hr and were harvested for WB. DMSO was used as vehicle control. (**K**) Cells transfected with WT p85α or PR1+PR2mut were treated with rapamycin or MK2206 for 48 hr before being harvested for IP with anti-HA.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.010](10.7554/eLife.06866.010)10.7554/eLife.06866.011Figure 2---figure supplement 2.PTEN in vitro lipid phosphatase activity was determined using a malachite green phosphatase assay with soluble PIP3 as the substrate.Endogenous PTEN proteins were immunoprecipitated in lysates using anti-PTEN antibody extracted from transfected cells and phosphatase activity was measured in triplicate. The activity was normalized to the levels of immunoprecipitated PTEN protein in each sample. \*p \< 0.05, compared with LacZ control. ^*\#*^p \< 0.05, compared with WT. The error bars represent S.D. of triplicates from two independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.011](10.7554/eLife.06866.011)

A number of feedback and feedforward regulations exist along the PI3K pathway, including negative feedback by S6K, positive feedback by mTORC2, and feedforward activation of mTOR by AKT ([@bib42]; [@bib17]; [@bib15]; [@bib39]; [@bib19]) ([Figure 2---figure supplement 1A,E,I](#fig2s1){ref-type="fig"}). The differences in AKT phosphorylation in presence of mutant or WT p85α raised the possibility that feedback or feedforward signaling mechanisms contributed to the observed changes in PTEN interactions and stability. We therefore examined whether these regulatory mechanisms affect the interaction between PTEN and WT p85α or the PR1+PR2mut. S6K but not Rictor siRNA altered AKT phosphorylation suggesting the existence of S6K-mediated but not mTORC2-mediated feedback in the KLE cell line, although the siRNAs decreased the expression of the proteins by 80% ([Figure 2---figure supplement 1B,C and 1F,G](#fig2s1){ref-type="fig"}). Importantly, the S6K and Rictor siRNAs had no effect on the PTEN interactions ([Figure 2---figure supplement 1D,H](#fig2s1){ref-type="fig"}). Interference with mTOR or AKT signaling by inhibitors also did not alter the interaction ([Figure 2---figure supplement 1J,K](#fig2s1){ref-type="fig"}). These data supported that the observed effects on PTEN stability result from the direct interaction with p85α, rather than from indirect feedback or feedforward-signaling mechanisms.

p85α homodimer enhances lipid phosphatase activity and membrane association of PTEN {#s2-4}
-----------------------------------------------------------------------------------

Phosphorylation of the PTEN C-terminal tail residues S380/T382/T383 (hereafter referred to as phosphorylated PTEN) regulates PTEN activity and stability, with the unphosphorylated counterpart (denoted hereafter as unphosphorylated PTEN) being more active ([@bib45]; [@bib35]). Consistent with a previous study showing that p85α preferentially binds unphosphorylated PTEN ([@bib36]), we found that p85α increased levels of unphosphorylated PTEN to a greater extent than that of phosphorylated PTEN ([Figure 2D--F](#fig2){ref-type="fig"}). Intriguingly, p85α also increased PTEN phosphatase activity towards soluble PIP~3~ substrate in a recombinant cell-free system ([Figure 2G](#fig2){ref-type="fig"}). This increase in phosphatase activity was recapitulated when PTEN was immunoprecipitated from WT p85α-transfected cell lysates indirectly using anti-p85α antibodies ([Figure 2H](#fig2){ref-type="fig"}) or directly using anti-PTEN antibodies ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Importantly, the increased phosphatase activity was reversed by mutations in PR1 and PR2 ([Figure 2H](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The PIP~3~ substrate of PTEN is located on the cell membrane with unphosphorylated PTEN exhibiting stronger membrane association than phosphorylated PTEN ([@bib35]). While p85α globally increased PTEN levels in the cytosol, membrane, and nucleus, p85α markedly increased unphosphorylated PTEN, but not phosphorylated PTEN, in the membrane ([Figure 2I](#fig2){ref-type="fig"}). Moreover, binding of recombinant PTEN to large multilamellar vesicles (LMVs), which represent model membranes used to assess protein-membrane association ([@bib13]; [@bib11]; [@bib28]), was increased in the presence of p85α ([Figure 2J](#fig2){ref-type="fig"}). Of note, the recombinant PTEN was predominantly in the unphosphorylated form. Together, these data suggest that p85α homodimers likely increase PTEN activity and membrane association of PTEN, in particular unphosphorylated active PTEN.

p85α homodimer decreases PTEN binding to the E3 ligase WWP2 {#s2-5}
-----------------------------------------------------------

The ubiquitin-proteasome pathway consists of a cascade of reactions with the substrate specificity being largely defined by E3 ubiquitin ligases. Therefore, we attempted to identify the PTEN E3 ligase that is regulated by the p85α homodimer. Consistent with previous studies ([@bib47]; [@bib32]), PTEN interacted with WWP2 and to a lesser extent with NEDD4 ([Figure 3A](#fig3){ref-type="fig"}). The E3 ligases c-cbl and cbl-b, which bind p85α ([@bib12]), did not bind PTEN. Importantly, WT p85α decreased the binding of PTEN to WWP2 without a demonstrable effect on NEDD4 binding ([Figure 3B](#fig3){ref-type="fig"}). Mutations in PR1 or PR2 increased interactions between PTEN and WWP2, suggesting that homodimerized p85α decreases PTEN ubiquitination by preventing WWP2 from binding PTEN. Again, siRNA and/or inhibitor-based interference with S6K, mTORC2, and AKT signaling had no effect on the interaction of PTEN with WWP2, suggesting that the increase in PTEN:WWP2 association is directly linked to the failure of the p85α mutants to bind PTEN, and not to indirect effects on other PI3K pathway components ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Indeed, both p85α ([Figure 3C](#fig3){ref-type="fig"}) and WWP2 ([@bib32]) bound to the PTEN phosphatase domain (residues 14--187), suggesting that p85α and WWP2 may compete for PTEN binding. A competition model is supported by the observation that WWP2 dose-dependently decreased the interaction between p85α and PTEN (Left, [Figure 3D](#fig3){ref-type="fig"}) and p85α-induced PTEN stabilization (Right, [Figure 3D](#fig3){ref-type="fig"}). Reciprocally, p85α inhibited binding of WWP2 to PTEN (Left, [Figure 3E](#fig3){ref-type="fig"}) and reversed the decrease in PTEN levels induced by WWP2 (Right, [Figure 3E](#fig3){ref-type="fig"}). In contrast, p85α PR1+PR2mut (which does not bind PTEN efficiently) failed to reverse the effect of WWP2 ([Figure 3F](#fig3){ref-type="fig"}). As an additional support of the competition model, siRNAs that target endogenous p85α or WWP2 decreased the interaction of PTEN with WWP2 or p85α, respectively, in an endometrial cancer cell line HEC1A that expresses high levels of p85α and WWP2 ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Together, these data indicate that p85α homodimers compete with WWP2 for binding to an overlapping site on the PTEN phosphatase domain and thereby inhibit PTEN ubiquitination.10.7554/eLife.06866.012Figure 3.p85α homodimer competes with E3 ligase WWP2 for PTEN binding.(**A**) KLE cells were harvested for IP with anti-PTEN and WB. Normal IgG was used as a negative control. (**B**) Cells transfected with WT p85α or PR mutants were harvested for IP after 72 hr. (**C**) Cells were co-transfected with p85α and full-length PTEN (FL) or deletion mutants (Left). PTEN proteins were immunoprecipitated by anti-Flag antibody and the immunoprecipitate was analyzed by WB (Right). (**D**) Cells transfected with HA-tagged p85α in the absence or presence of an increasing amount of WWP2 were collected for IP with HA (Left) or WB (Right). (**E**, **F**) Cells transfected with Myc-tagged WWP2 in the absence or presence of an increasing amount of WT p85α (**E**) or PR mutant (**F**) were collected for IP with Flag for PTEN (Left) or WB (Right). LacZ was used as control. Numerical values below each lane of the immunoblots represent quantification of the relative protein levels by densitometry. PBM, phosphoinositide-binding motif.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.012](10.7554/eLife.06866.012)10.7554/eLife.06866.013Figure 3---figure supplement 1.(**A**, **B**) KLE cells co-transfected with WWP2 and 10 nM siRNA targeting S6K or NS control for 72 hr were harvested for WB directly (**A**) or IP with anti-Flag and WB (**B**).(**C**, **D**) Cells co-transfected with WWP2 and 10 nM siRNA targeting Rictor or NS control for 72 hr were harvested for WB (**C**) or IP with anti-Flag (**D**). (**E**) Cells transfected with WWP2 were treated with rapamycin (500 nM) or MK2206 (1 μM) for 48 hr before being harvested for IP with anti-Flag.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.013](10.7554/eLife.06866.013)10.7554/eLife.06866.014Figure 3---figure supplement 2.(**A**, **B**) HEC1A cells were transfected with 10 nM siRNA targeting WWP2 (**A**) or p85α (**B**) for 72 hr.The efficiency of the siRNAs was confirmed by WB. NS siRNA was used as control. (**C**, **D**) Cells transfected with 10 nM siRNA targeting WWP2 (**C**) or p85α (**D**) or NS control for 72 hr were harvested for IP with anti-PTEN and WB.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.014](10.7554/eLife.06866.014)

PTEN bound to p85α homodimers does not bind WWP2 {#s2-6}
------------------------------------------------

To validate this model, analytical gel filtration was performed to characterize the association and competition between p85α, p110α, PTEN, and WWP2. PTEN was recovered in fractions that were free of p110α ([Figure 4A](#fig4){ref-type="fig"}) and binding of p85α to p110α and to PTEN was mutually exclusive ([Figure 4B](#fig4){ref-type="fig"}). Coomassie blue staining of p85α immune complex in p110α-containing fractions indicated the existence of other proteins ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) including several known p85α:p110α heterodimer-binding proteins ([@bib46]; [@bib38]; [@bib26]; [@bib1]) ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Likewise, consistent with a previous study ([@bib36]), p85α-PTEN existed in a high-molecular weight multi-protein complex ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). The majority of unphosphorylated PTEN eluted in fractions containing high levels of p85α ([Figure 4A](#fig4){ref-type="fig"}). Immunoprecipitation (IP) confirmed that unphosphorylated PTEN but not phosphorylated PTEN was associated with p85α ([Figure 4B](#fig4){ref-type="fig"}). Strikingly, no interaction between WWP2 and PTEN was detected in fractions that contained p85α ([Figure 4C](#fig4){ref-type="fig"}), indicating that WWP2 only binds PTEN that is not bound to p85α in the cell-derived complex.10.7554/eLife.06866.015Figure 4.Binding of PTEN to WWP2 and to p85α homodimer is mutually exclusive.(**A**--**F**) Cell lysates from KLE cells transfected with WT p85α (**A**--**C**) or combined PR1 and PR2 mutant (PR1+PR2) (**D**--**F**) were fractionated using a gel filtration column and the indicated fractions were analyzed by WB (**A**, **D**) or pooled for IP with anti-p85α antibody (**B**, **E**) or anti-PTEN antibody (**C**, **F**). Input, total lysates before being subjected to gel filtration; F, fraction; MW, molecular weight.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.015](10.7554/eLife.06866.015)10.7554/eLife.06866.016Figure 4---figure supplement 1.(**A**-**B**) KLE cells were transfected with WT p85α for 72 hr.Whole cell lysates were then fractionated using a gel filtration column and the indicated fractions were pooled for IP with anti-p85α antibody. The immunocomplexes were subjected to SDS-PAGE followed by Coomassie Blue staining (**A**) or WB (**B**) with indicated antibodies. F, fraction.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.016](10.7554/eLife.06866.016)

Next, we determined whether complex formation is altered when p85α homodimerization is disrupted by the PR1+PR2mut. Intriguingly, while distribution of p110α was unchanged, there was a shift in the distribution of unphosphorylated PTEN to fractions lacking p85α ([Figure 4D](#fig4){ref-type="fig"}), suggesting that the PR mutations decreased the interaction between PTEN and p85α. Moreover, we observed a marked accumulation of PR1+PR2mut in fraction 39 which was absent in WT p85α-transfected cells ([Figure 4A](#fig4){ref-type="fig"}) that most likely represents monomeric p85α ([Figure 4D](#fig4){ref-type="fig"}). Importantly, PTEN did not bind PR1+PR2mut in fraction 39 ([Figure 4E--F](#fig4){ref-type="fig"}). p110α was not detected in fraction 39 likely because p85α was in excess of p110α. Together, these results confirm that p110α binds monomeric p85α, while unphosphorylated PTEN binds homodimeric p85α and further that the binding of PTEN to WWP2 and to homodimeric p85α is mutually exclusive.

Cancer patient-derived *PIK3R1* mutations target the p85α homodimerization surface {#s2-7}
----------------------------------------------------------------------------------

Mutations in *PIK3R1* can contribute to tumorigenesis ([@bib20]; [@bib8]). Given p85α homodimerization is a key regulator of PTEN and PI3K pathway activation status, mutations that affect p85α homodimerization or association with PTEN would be expected to increase PI3K pathway activation and tumorigenesis. We therefore searched our in-house endometrial cancer data set ([@bib8]) and The Cancer Genome Atlas (TCGA) ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) ([@bib4]) for cancer patient-derived *PIK3R1* mutations that could target p85α homodimerization. Among mutations in the BH domain, E175K (in skin cutaneous melanoma; TCGA) and I177N (in endometrial cancer ([@bib8])) localize to the BH:BH dimer interface ([Figure 1F](#fig1){ref-type="fig"}) and occur at sites that are highly conserved across species. I177 is a key residue of the BH:BH hydrophobic core. Substitution of the bulky hydrophobic isoleucine by a smaller and partly polar residue would be predicted to weaken homodimerization. Indeed, I177N decreased homodimer formation, decreased PTEN binding, increased ubiquitinated PTEN, and increased phosphorylated AKT consistent with PI3K pathway activation ([Figure 5A--C](#fig5){ref-type="fig"}). I177N also promoted interleukin-3 (IL3)-independent survival of the IL3-dependent BaF3 cells ([Figure 5D](#fig5){ref-type="fig"}) ([@bib20]; [@bib8]), consistent with the oncogenic potential of the mutant. These results indicate that I177N could act as an oncogenic mutation at least in part by perturbing p85α homodimerization. Of note, I177N has biochemical phenotypes similar to E160\*, which is a patient-derived p85α mutant that disrupts p85α homodimerization and destabilizes PTEN protein ([@bib8]). In contrast, E175 localizes to the polar and charged rim of the BH:BH interface with our model predicting that the E175K mutation would only have minimal influence on the BH:BH interaction ([Figure 1F](#fig1){ref-type="fig"}). Indeed, biochemical analysis failed to detect effects of E175K on PTEN levels, ubiquitination, p85α binding, and pAKT as well as on proliferation of BaF3 ([Figure 5A--D](#fig5){ref-type="fig"}).10.7554/eLife.06866.017Figure 5.Oncogenic cancer patient-derived *PIK3R1* mutation perturbs p85α homodimerization leading to PI3K pathway activation.(**A**) KLE cells co-transfected with Flag-tagged WT p85α (Flag-WT) and HA-tagged WT p85α or patient-derived p85α BH domain mutants were collected for IP with anti-HA and WB. (**B**, **C**) Cells transfected with WT p85α or mutants were collected for IP with anti-PTEN and WB with anti-ubiquitin (**B**) or directly for WB (**C**). PTEN protein levels were normalized prior to IP by using proportionally different amounts of lysates. Numerical values below each lane of the immunoblots represent quantification of the relative protein levels by densitometry. (**D**) Ba/F3 cells transfected with WT p85α or mutants were cultured without interleukin-3 for 4 weeks and harvested for viability assays. \*p \< 0.05, compared with WT. The error bars represent S.D. of triplicates from three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.017](10.7554/eLife.06866.017)10.7554/eLife.06866.018Figure 5---figure supplement 1.*PIK3R1* mutations from The Cancer Genome Atlas (TCGA) data sets across tumor lineages are represented by lollipops (green, missense; red, nonsense, frameshift, or splice; black, in-frame deletion/insertion; purple, different types of mutations at the same site).The diagram was adopted from the cBioPortal (<http://www.cbioportal.org/public-portal/>).**DOI:** [http://dx.doi.org/10.7554/eLife.06866.018](10.7554/eLife.06866.018)

Structural modeling of the homodimerized p85α:PTEN complex reveals a cancer patient-derived p85α mutant that is defective at the PTEN interaction interface {#s2-8}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Given the pathophysiological relevance of the p85α:PTEN interaction, we next investigated whether the PTEN-interacting interface on p85α would be mutated in cancer patients. To this end, we compiled a total of 16 experimental, bioinformatics, structural and functional constraints (see [Appendix 1](#app1){ref-type="app"}), including our observation that PTEN and small GTPases bind the p85α BH domain ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}) non-competitively, to compute the most likely structural model for the homodimerized p85α:PTEN complex ([Figure 6A](#fig6){ref-type="fig"} and [Appendix 1](#app1){ref-type="app"}). In this model, the hydrophobic and charged residues I127/I133/E137 of the p85α BH domain are within the proposed PTEN-binding surface. We therefore engineered a I127A/I133A/E137A triple p85α mutant. The mutant decreased PTEN binding without altering p85α homodimerization ([Figure 6B](#fig6){ref-type="fig"}). Combined mutations of I127A/I133A/E137A and PR2, which also contributes to interaction with PTEN ([Figure 1C](#fig1){ref-type="fig"}), resulted in further inhibition of PTEN binding ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), indicating that these residues are cooperative in binding PTEN.10.7554/eLife.06866.019Figure 6.Molecular model of the p85α homodimer:PTEN complex reveals cancer patient-derived p85α mutant with decreased PTEN binding.(**A**) Schematic theoretical molecular working model of the homodimerized p85α:PTEN. This speculative model has been constructed by integrating experimental data, physical constraints, and computational scoring functions (see [Appendix 1](#app1){ref-type="app"} for details). For simplicity, only one PTEN molecule is shown. The PTEN molecular structure is taken from PDB 1D5R ([@bib28]). The model orientation corresponds to the view from the membrane toward the cytosol. Encircled numbers indicate locations of: 1, PTEN phosphatase active site; 2, the side chain of p85α W298, located at the start of the flexible PR2 sequence; 3, approximate position of the PTEN K13 and of the p85α triple mutation I127/I133/E137. (**B**) KLE cells co-transfected with Flag-tagged WT p85α (Flag-WT) and HA-tagged WT p85α or mutants were collected for IP and WB. (**C**) Cells transfected with WT p85α or mutants were harvested for IP and WB. PTEN protein levels were normalized prior to IP by using proportionally different amounts of lysates. (**D**) Cells transfected with WT p85α or mutants were harvested for WB. Numerical values below the immunoblots represent relative protein levels by densitometry. (**E**) Ba/F3 cells transfected with WT p85α or mutants were cultured without interleukin-3 for 4 weeks and harvested for viability assays. \*p \< 0.05, compared with WT. The error bars represent S.D. of triplicates from three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.019](10.7554/eLife.06866.019)10.7554/eLife.06866.020Figure 6---figure supplement 1.(**A**) KLE cells co-transfected with Flag-tagged WT p85α (Flag-WT) and HA-tagged WT p85α or mutants were harvested for IP with anti-HA and then subjected to WB.The mutated amino acids are highly conserved residues potentially for small GTPase binding. (**B**) Cells were co-transfected with HA-tagged p85α in the absence or presence of increasing amounts of PTEN (Left) or Cdc42 (Right). The lysates were collected for IP with anti-HA antibody. (**C**) Cells transfected with HA-tagged WT p85α or mutants were harvested for IP with anti-HA and WB. Numerical values below the immunoblots represent quantification of the relative protein levels by densitometry. (**D**) 62 patient-derived *PTEN* phosphatase domain missense mutations from our in-house endometrial cancer data set and TCGA were mapped onto the surface of PTEN. These mutations form three clusters. Red: mutations in the active site and membrane anchoring regions (27 mutations out of 62); magenta: mutations of the predicted p85α binding site (19/62); orange: mutations of the phosphatase-C2 interface (5/62); yellow: mutations of a site with unknown function (11/62). Blue spheres represent a bound L(+)-tartrate molecule found in the PTEN crystal structure (1D5R), which is thought to mimic interactions of PTEN with substrate phosphates.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.020](10.7554/eLife.06866.020)

Strikingly, in an extension of our previous study to additional tumor samples ([@bib8]), we detected a p85α I133N mutant in an endometrial cancer patient. I133N led to a decrease in PTEN binding but not p85α homodimer formation ([Figure 6B](#fig6){ref-type="fig"}). Comparable to I177N, I133N increased PTEN ubiquitination, induced PI3K pathway activation, and enhanced survival of BaF3 cells ([Figure 6C--E](#fig6){ref-type="fig"}). Together, these data are consistent with I133N being another oncogenic mutation that blocks stabilization of PTEN. Further, 19 of 62 cancer patient-derived *PTEN* missense mutations in the phosphatase domain mapped to the proposed p85α interaction surface ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), suggesting that additional *PTEN* mutations may function through disrupting the association of PTEN with p85α.

Discussion {#s3}
==========

The PI3K pathway is tightly regulated at multiple levels, for example, through PTEN, INPP4B and negative feedback loops such as that mediated by activated S6K ([@bib17]). In this study, we provide a mechanistic model of how the p85α regulatory component of PI3K itself plays a dual role in regulating the PI3K pathway.

A molecular excess of p85 over p110 has been observed ([@bib44]). It has been suggested that p110-free p85 sequesters the adaptor protein insulin receptor substrate (IRS) through an nSH2-iSH2-cSH2 fragment-mediated interaction, thereby competing with the p85:p110 heterodimer for IRS binding and limiting the extent of insulin-induced PI3K signaling ([@bib31]). Our results herein suggest an additional but compatible mechanistic model of how free p85α negatively regulates the PI3K pathway.

Our data support a model in which stable p85α homodimerization requires a simultaneous SH3:PR1 interaction in trans and a BH:BH interaction around residue M176. These homodimers can form in absence of other proteins. Collectively, our results illustrate opposing functions of the p85α monomer and homodimer. As a homodimer, p85α competes with WWP2 for binding to the PTEN phosphatase domain and protects PTEN against WWP2-mediated degradation ([Figure 7](#fig7){ref-type="fig"}). The p85α homodimer also enhances the activity and membrane association of PTEN. Thus, homodimeric p85α indirectly downregulates PI3K signaling. Although the p85α homodimer does not bind p110α, it remains to be ascertained whether the nSH2-iSH2-cSH2 fragment of p85α homodimer can bind phosphotyrosines in activated cell surface molecules and thereby recruit PTEN to the activation nidus. As a monomer, p85α binds p110α in a 1:1 ratio ([@bib27]). This interaction is intrinsically inhibitory but it stabilizes p110α and allows activation of the p85α:p110α complex upon stimulation, promoting propagation of ligand-dependent PI3K pathway signaling. We therefore propose that the p85α monomer--dimer equilibrium is a gatekeeper for PI3K pathway activation.10.7554/eLife.06866.021Figure 7.Schematic working model of how homodimerized p85α promotes PTEN stabilization and lipid phosphatase activity.Our data support a p85α homodimer model that includes intermolecular interactions between SH3:PR1 in trans and BH:BH interactions between protomers. Key contact residues at the interfaces are shown as blue lollipops. The homodimerized p85α binds PTEN at least partly through the PR2 domain and the indicated residues (red lollipops) in the BH domain. This interaction prevents PTEN from binding to the E3 ligase WWP2, thereby inhibiting PTEN ubiquitination. The homodimerized p85α preferentially binds unphosphorylated PTEN, which has an open conformation and is more active. Independent of stabilizing PTEN protein, homodimerized p85α also enhances PTEN lipid phosphatase activity and association of unphosphorylated PTEN with the membrane where the PIP~3~ substrates localize. It remains unknown whether homodimerized p85α induces conversion of unphosphorylated PTEN from its close, inactive phosphorylated counterpart.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.021](10.7554/eLife.06866.021)

Homodimeric p85α preferentially binds unphosphorylated PTEN, which is less stable yet more active than its phosphorylated counterpart ([@bib45]; [@bib35]; [@bib36]). Phosphorylated PTEN is in a 'closed' conformation in which the phosphatase domain is auto-inhibited by the C-terminal tail. In contrast, unphosphorylated PTEN is in an 'open' conformation with the catalytic domain exposed, leading to increased membrane association and activity. The observation that p85α homodimers selectively target the unphosphorylated and less stable form of PTEN fits into a mechanistic model wherein in the absence of excess p85α, and thus, in the absence of p85α homodimers, the unphosphorylated and active PTEN is destabilized, allowing PI3K pathway activation initiated by p110α-bound p85α monomers. Further, our data showed that p85α can bind PTEN, promote PTEN activity and membrane binding in the absence of other proteins. Therefore, the interaction between p85α and PTEN appears to be direct and does not require the presence of other proteins, although p85α and PTEN are part of a high-molecular weight complex containing multiple other proteins.

Based on our data, we speculate that the dynamic formation of p85α homodimers plays a role in the termination of signals initiated at the activation nidus by monomeric p85α-bound p110α. There are several possible scenarios in which the dynamics of p85α homodimer formation could be altered. For example, our data in this and previous studies ([@bib8]) suggested that p110α can disrupt p85α homodimerization by decreasing the abundance of p110α-free p85α. An increase in p110α levels, such as through *PIK3CA* gene amplification, might therefore decrease p85α homodimerization leading to PTEN destabilization. Secondly and intriguingly, *PIK3R1* also encodes for two functional splice variants, p55α and p50α, which lack the domains required for homodimerization. By sequestering p110α, p55α, and p50α could increase the amount of free p85α. Moreover, naturally occurring somatic *PIK3R1* mutations (I177N and E160\*) and likely others disrupt p85α homodimerization, including mutations at P99 in PR1, R162\*, frame shifts at Q153, D168, H180, V181, and L182 ([@bib8]; [@bib4]). Further, a patient-derived p85α mutant I133N that targets the PTEN interaction interface was identified using our speculative theoretical p85α:PTEN model. The *PIK3R1* mutations may hence be selected, at least in part, by effects on p85α homodimer formation and PTEN destabilization. Intriguingly, the proposed p85α-binding site on PTEN also overlaps with a PTEN surface that is frequently mutated in cancers (in 30% of the missense mutations of the phosphatase domain), suggesting that some of these PTEN mutants may disrupt association with p85α therefore decreasing PTEN protein stability and activity.

In addition to predicting mutations that disrupt homodimerization or PTEN interaction interfaces, the homodimerized p85α:PTEN model also offers possible mechanistic explanations for experimental observations. For example, the region outlined by I127/I133/E137 is close to in space to PR2 and both regions could thus together constitute a binding site for PTEN, possibly explaining the cooperativity between these residues in PTEN binding ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). The model also proposes that PTEN:BH interaction renders a site of PTEN ubiquitination K13 inaccessible, suggesting a mechanism for how p85α could protect PTEN from ubiquitination ([Figure 6A](#fig6){ref-type="fig"}). Moreover, the model predicts that the phosphorylated C-terminal tail of the 'closed' inactive PTEN competes with the p85α PR2 for binding to the phosphatase domain of PTEN, providing a plausible explanation for why p85α selectively binds unphosphorylated PTEN.

One key insight from our efforts to establish a speculative theoretical p85α:PTEN model was that our experimental constraints (derived from our mutational analysis, and from our observation that the PTEN:p85α association is compatible with the p85α:GTPase interaction and with PTEN catalytic activity) cannot be satisfied by a structural model in which one PTEN phosphatase domain binds simultaneously to both BH domains of the p85α homodimer. Instead, our theoretical model proposes that the PTEN phosphatase domain binds to the BH domain of only one p85α protomer, opposite to the GTPase-binding site ([Figure 6A](#fig6){ref-type="fig"} and [Appendix 1](#app1){ref-type="app"}). To explain the requirement of a stable p85α homodimer for PTEN binding and protection, our model suggests that (i) although the PTEN phosphatase domain only binds to one BH molecule, the flexible N-terminal 13 residues of PTEN may interact with the second BH molecule of the dimer (in our model, PTEN residue 14 is close to and its main chain orients towards the BH:BH domain interface) and/or (ii) homodimerization allosterically affects the PTEN-binding site on BH (p85α residues I127/I133/E137 are close to the BH:BH homodimerization interface). Although our molecular model is supported by experimental data and showed strong predictive power, it remains hypothetical and we cannot exclude that other structural complexes could satisfy our constraints, or that some of the constraints are wrong. For instance, our model assumes that the PTEN:p85α(:GTPase) assembly is symmetric and homogenous. Yet, there could be other possible scenarios, for example, where only one of two p85α homodimer--bound PTEN molecules is able to reach the membrane with its catalytic site, or where only one p85α molecule of the homodimer binds to a GTPase, allowing a PTEN molecule to bind to both p85α molecules of the dimer\'s other side. Moreover, the contribution of flexible regions in protein interactions makes the structural modeling of these interactions necessarily more uncertain. Accordingly, uncertainty in our speculative PTEN:p85α complex model arises from the lack of precise information concerning the structure and possible interactions of the flexible regions of PTEN (the first 13 residues) and p85α (the PR2 region, and the loop between residues 123 and 130). Thus, while currently representing a useful working model for guiding and informing experimental analysis, our theoretical PTEN:p85α structure requires confirmation by an experimental structure.

In conclusion, our study suggests that the PI3K pathway activation status can be influenced by the relative levels of p110, p85α, and PTEN. These findings lend new insight to how changes in p110 levels through amplification or *PIK3R1* mutations could lead to PI3K pathway hyperactivation and thus contribute to diseases such as cancer. By decreasing PTEN expression and activity, these non-nSH2-iSH2-cSH2 *PIK3R1* mutations may affect sensitivity to particular targeted therapeutics. Indeed, p110β rather than p110α has been proposed as the primary target in cells with PTEN protein loss ([@bib21]). Targeting p85α homodimerization or the p85α:PTEN interaction may represent a new avenue for cancer treatment.

Materials and methods {#s4}
=====================

Homology modeling {#s4-1}
-----------------

The complex between p85α SH3 and p85α PR1 peptide P^87^KPRPPRPLPVAP was constructed based on the crystal structures of p85α SH3:HSKRPLPPLPSL (3I5R) and Fyn SH3: PPRPLPVAPGSSKT (1A0N). This structure was refined using the Rosetta energy function as implemented in FlexPepDock ([@bib30]). Construction of the PTEN:p85α molecular interaction model is detailed in the [Appendix 1](#app1){ref-type="app"}.

Protein production {#s4-2}
------------------

The p85α SH3 (residues 1--81) and PR1-BH domains (residues 79--301) were produced in *E. coli* BL21 cells as a 6His-fusion protein using the pET28b expression vector (Novagen). Protein production was induced by 0.4 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37°C. Cells were lysed using mild sonication, and proteins were purified to homogeneity by immobilized nickel affinity column using standard procedures. Eluted protein was dialyzed into 20 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 5 mM DTT and applied to S75 (Pharmacia) size-exclusion chromatography. Fractions containing pure SH3 were pooled and concentrated.

The p85α SH3-PR1-BH-PR2 fragment (residues 1--333) and WT p85α were produced in E. *coli* BL21 cells as GST-fusion proteins using a pGex6P-2 expression vector (GE Healthcare, Pittsburgh, PA). Protein expression was induced by 0.4 mM IPTG at 18°C overnight, and proteins were purified by GST affinity column. Eluted proteins were dialyzed into 20 mM Tris pH 8.0, 150 mM NaCl, 5 mM DTT. WT p85α was further purified using MonoQ 10/100 column and eluted by a linear NaCl gradient (20 mM Tris pH 8.0, 1M NaCl, 5 mM DTT). Finally, p85α~1-333~ C147S and WT p85α were applied to a Superdex200 16/600 (GE Healthcare) size-exclusion chromatography. Fractions containing pure proteins were pooled and concentrated.

MST {#s4-3}
---

Proteins were fluorescently labeled with Alexa^647^ according to the manufacture's protocol (L001, Nanotemper technologies, Germany). Labeled proteins were kept at 20 nM. The unlabeled protein was titrated starting at 50,000 nM and serially diluted in 1:1 ratio in reaction buffer (20 mM sodium phosphate pH 8, 150 mM NaCl, 2 mM EDTA, 5 mM DTT). The measurements were performed at 40% LED and 20, 40, and 60% MST power on NanoTemper Monolith NT.115. Data were analyzed using NT Analysis Software (Nanotemper technologies, Germany).

ITC {#s4-4}
---

p85α SH3 and GST-ΔSH3 p85α were dialyzed in degassed ITC buffer (10 mM sodium phosphate pH 7.5, 150 mM NaCl, 5 mM DTT). Titrations for p85α SH3:PR1 peptide interaction were carried out on a MicroCal ITC200 at 25°C by serially injecting 2 μl of peptide P^87^KPRPPRPLPVAP into the measurement cell that contained p85α SH3 at a concentration of 100 μM. GST-ΔSH3 p85α and p85α SH3 titrations were carried out similarly, with SH3 in the syringe (400 μM) and ΔSH3 p85α in the cell. Ligand concentrations were 10× the cell concentration. Titrations were analyzed using Origin software.

Sedimentation velocity {#s4-5}
----------------------

The experiments were conducted on a Beckman Coulter XL-A analytical ultracentrifuge at 20°C using absorption optics. Samples were loaded at 17, 9, 5, 3, and 0.7 µM in a standard cell (400 μl). Data were acquired (120 scans) in intensity mode at 280 nm at 6-min intervals with a rotor speed of 48 krpm for p85α PR1-BH, 45 krpm for p85α SH3-PR1-BH-PR1, and 42 krpm for WT p85α. Data were analyzed in SEDFIT 14.3e ([@bib40]) using the continuous c(s) distribution model. Solution densities ρ and viscosities η were calculated using the program SEDNTERP 1.09 ([@bib9]). Analyses of sedimentation coefficients were carried out using s range of 0.05--10 with linear resolution of 100 and confidence levels of 0.95. Fits were achieved with root mean square deviations ranging from 0.0030 to 0.0055 absorbance units. Sedimentation coefficients were corrected to standard conditions at 20°C in water, *s*^*o*^~*20,w*~ using SEDNTERP 1.09.

Sedimentation equilibrium {#s4-6}
-------------------------

The experiments were performed on a Beckman Optima XL-A analytical ultracentrifuge at 20°C. Samples were loaded at 1.0, 0.5, and 0.25 mg/ml into a 2-channel, 12-mm path-length cells (100 μl). Data were acquired at 11.8, 12.8, 13.8 krpm, as an average of 5 absorbance measurements at 280 nm using a radial spacing of 0.001 cm. Experiments were started from zero to the lowest rotor speed by taking scans at 2-hr intervals and testing for equilibrium by determining the differences between successive scans in SEDFIT. The rotor speed was then increased and the process repeated at each rotor speed studied and sedimentation equilibrium was achieved within 48 hr. Data for the individual proteins collected at different speeds and loading concentrations at 280 nm were sorted and assembled in SEDFIT and analyzed globally in terms of monomer--dimer--tetramer (monomer-m-mer-n-mer ) or monomer--dimer model in SEDPHAT 10.58e ([@bib41]) with the implementation of mass conservation. The error analysis was performed with 500 (1000 for p85α PR1-BH) Monte Carlo iterations at the 95% confidence level.

Cell lines, plasmids, and transfection {#s4-7}
--------------------------------------

The KLE cell line was provided by Dr. Russell Broaddus (M.D. Anderson Cancer Center). The p85α knockout MEFs were obtained from Dr Lewis C. Cantley\'s lab (Weill Cornell Medical College, New York, NY). The *PIK3R1* cDNA has been described ([@bib8]). Specific mutations were generated using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technology, Santa Clara, CA). Transfection of plasmids was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). All ON-TARGET plus siRNAs and control siRNA were obtained from Dharmacon (Lafayette, CO) and introduced into the cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer\'s instructions. We utilized two independent siRNA sequences per target. The sequences of the siRNAs are p85α-CCAACAACGGUAUGAAUAA and UAUUGAAGCUGUAGGGAAA; WWP2- AGACACGUCCGUUGGGCAG and GCUUCACCCUCCCUUUCUA; S6K- CAUGGAACAUUGUGAGAAA and GGAAUGGGCAUAAGUUGUA; Rictor- GACACAAGCACUUCGAUUA and GAAGAUUUAUUGAGUCCUA.

IP and Western blotting {#s4-8}
-----------------------

Whole cell lysates (25 µg) extracted with radioimmunoprecipitation assay buffer (RIPA) lysis buffer were loaded onto sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Primary antibodies specific to PTEN, p110α, total Akt, phospho-Akt (Thr^308^ or Ser^473^) and total p110α (Cell Signaling Technology, Danvers, MA), HA (Covance, Princeton, NJ), Myc and FLAG (Sigma--Aldrich, St. Louis, MO), ubiquitin (Enzo Life Sciences, Farmingdale, NY) were used. For IP, cell lysates (1 mg) were immunoprecipitated with antibodies against HA or Flag (1 μg) or PTEN (1:500) overnight at 4°C. The immune complexes were collected by incubation with protein A/G agarose (Santa Cruz) for 4 hr before being resolved by SDS-PAGE.

Gel filtration {#s4-9}
--------------

Cells were lysed in a hypotonic lysis buffer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl~2~, 10 mM KCl, 1 M EDTA, 0.1% NP-40 and protease inhibitors. Lysates (5 mg) clarified by ultracentrifugation (30,000×*g*, 45 min, 4°C) were applied to Superose 6, 10/300 GL column (GE Healthcare) run at 4°C in binding buffer (0.1% NP-40) on a BioLogic HR system (BioRad, Hercules, CA). Elution was performed at 0.1 ml/min, and 0.5-ml fractions were collected. Fractions were analyzed by Western blotting (WB) or pooled for IP with anti-p85α (1:50) (Abcam, Cambridge, MA) or PTEN (1:500) antibody.

Ba/F3 survival assay {#s4-10}
--------------------

The assay was described previously ([@bib8]). In brief, Ba/F3 cells transfected with WT *PIK3R1* or mutants were cultured in medium without IL-3 for 4 weeks. Cell viability was evaluated using PrestoBlue (Invitrogen) for mitochondrial dehydrogenase activity.

Lipid phosphatase assay {#s4-11}
-----------------------

In vitro PTEN lipid phosphatase activity was determined using malachite green phosphatase assay kit (Echelon Biosciences, Inc., Salt Lake City, UT). Briefly, protein lysates (1 mg) were subjected to IP of endogenous PTEN using anti-PTEN or anti-p85α antibody and the bead complex was resuspended in PTEN reaction buffer before PIP~3~ substrate was added to initiate the reaction. Reaction mixture with PIP~3~ but not lysate was used for background correction. The reaction was stopped after 4-hr incubation at 37°C and the supernatant was separated from the beads for activity detection. The beads were used for WB to quantify immunoprecipitated PTEN. The activity was normalized to immunoprecipitated PTEN level in each sample. To assess the activity of recombinant PTEN, 1 μg of PTEN was incubated with 1 μg of recombinant p85α in buffer containing 50 mM Tris--HCl pH 8.0, 50 mM NaCl, and 10 mM MgCl~2~ (PTEN reaction buffer without DTT) at room temperature for 1 hr before being subjected to the reaction.

Phospholipid binding assay {#s4-12}
--------------------------

The assay was performed in reference to previous studies ([@bib13]; [@bib11]; [@bib28]). Formation of LMVs composing of brain phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC) (molar ratio 40:10:50) resuspended in buffer containing 50 mM Tris-Cl, 150 mM NaCl, 10 mM DTT, 0.001% Triton X-100 (pH 8.0) was obtained from Avanti Polar Lipids, Inc. (Alabaster, Al). PTEN recombinant protein (5 µg) was incubated in 300 µl of buffer containing 50 mM Tris-Cl, 150 mM NaCl, and 0.001% Triton X-100 (pH 8.0) in the presence or absence of 5 µg of recombinant p85α for 1 hr at 25°C. LMVs (150 μg) were then added and the mixture was incubated for another 15 min at 25°C. After centrifugation at 12,000×*g* for 10 min, the phospholipid pellets were dissolved in SDS sample buffer. The proteins in the supernatants corresponding to the lipid-unbound population were precipitated with 20% trichloroacetic acid and the precipitates were dissolved in SDS sample buffer. Equal amounts of samples from the supernatants and pellets were analyzed by SDS-PAGE and Coomassie Brilliant Blue R-250 staining.

Statistical analysis {#s4-13}
--------------------

All experiments were independently repeated at least twice, and data are presented as mean values ± SD. The significance of differences was analyzed by a Student's t test. Significance was accepted at the 0.05 level of probability (p \< 0.05).
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Supplemental material on computational modeling of homodimerized p85α:PTEN complex {#s7}
==================================================================================

In the following, we describe how we combined all available data to establish the most likely theoretical working model for the p85α homodimer:PTEN complex. We note that although the p85α:PTEN model is based on experimental constraints and supported by mutational analysis, the model remains speculative.

A) Establishing a molecular model for the SH3-BH fragment {#s7-1}
---------------------------------------------------------

### (i) Establishing the dimeric BH domain model {#s7-1-1}

The molecular basis for the dimeric BH domain is derived from the C2-symmetric dimer in the crystal structure of p85α residues 105--320 (PDB accession 1PBW; only residues 115--309 are modeled in the crystal structure). We validated the crystallographic BH dimer model by mutational analysis (see main text and [Figure 1G](#fig1){ref-type="fig"}).

### (ii) Construction of the molecular model for GTPase binding to p85α {#s7-1-2}

The p85α BH domain binds small GTPases (Rab4, Rab5, Cdc42, Rac1) and functions as a GTPase-activating protein (GAP) ([@bib49]; [@bib6]). We found that mutations in the GTPases binding site of p85α did not affect PTEN binding and that Cdc42 and Rab5 did not compete with PTEN for binding to p85α ([Figure 6---figure supplement 1A-B](#fig6s1){ref-type="fig"}). The interaction between p85α and small GTPases can be modeled based on the available crystal structure of Cdc42 bound to Cdc42GAP (1GRN). Cdc42GAP is 22% identical to p85α BH. The structure of Cdc42-bound Cdc42GAP was superimposed onto the structure of p85α BH (rmsd: 2.48 Å; [Appendix figure 1](#fig8){ref-type="fig"}). Using the Cdc42:Cdc42GAP positioning from this superimposition, Cdc42 was transferred to p85α BH to produce a BH:Cdc42 model. The BH:Cdc42 model produced no important clashes and put the BH arginine 151 into the position of the Cdc42GAP R305, an important residue for GAP function and interaction, thus confirming the positioning of the GTPase on BH, at least to a domain-resolution precision. We then used the structure of this BH:Cdc42 model to produce a BH:Rab5 model by using bound Cdc42 as a template for bound Rab5 (25% seq. identity). As an alternative approach, we superimposed the crystal structure of GTP analogue-bound Rab5 (1R2Q) onto GAP-bound Cdc42. Both Rab5 models were highly similar (rmsd = 1.12 Å). All obtained models of BH:GTPase are sufficiently structurally compatible and plausible (shape complementarity without steric hindrance) to serve our purpose of delineating the approximate region on BH occupied by a biologically relevant GTPase.10.7554/eLife.06866.022Appendix figure 1.Superimposition of the crystallographic complex Cdc42GAP (light green) bound to Cdc42 (dark green) (1GRN) onto p85α BH (black) and the crystal structure of Rab5 (yellow; 1R2Q).The GTP analogue (magenta) and the important catalytic arginine residue (blue) are highlighted.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.022](10.7554/eLife.06866.022)

We next tested if GTPase binding is stereochemically compatible with formation of the BH dimer. BH:Rab5 did not show any clashes in the context of dimeric BH. Cdc42 showed minor clashes in the region between 121 and 136, but this region is a flexible loop--helix--loop region, with above-average B-factors in the crystal structure, and is expected to adjust to the BH:BH dimer surface. However, to avoid any additional ambiguity due to structural rearrangements, we used Rab5 as the GTPase model in our subsequent analysis.

As seen in the resulting 2x(BH:Rab5) complex ([Appendix figure 2](#fig9){ref-type="fig"}), compatibility of GTPase binding to BH with PTEN interaction results in strong spatial constraints for both the placement of PTEN and the placement of the SH3:PR1 interaction with respect to the BH domain.10.7554/eLife.06866.023Appendix figure 2.Model for Rab5 bound to the BH domain. Left and right panel are 90° views.Cyan: Residues mutated in the GTPase-binding site that did not affect PTEN binding.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.023](10.7554/eLife.06866.023)

### (iii) Positioning of the SH3:PR1 interaction relative to the BH:BH dimer {#s7-1-3}

Our results strongly suggested that the p85α SH3 domains interact with the PR1 region in trans with a canonical class I PXXP interaction ([Figure 1A](#fig1){ref-type="fig"}). To ascertain that this type of interaction is physically compatible with the crystallographic BH dimer, we used the program BUNCH ([@bib23]) as a fast and convenient tool, because BUNCH produces stereochemically plausible structures, and can include symmetry and contact constraints. Because BUNCH needs a SAXS curve as input to run, we simply simulated a large array of SAXS data sets in order to run BUNCH. We used ten different simulated data sets (calculated based on models with different SH3 positions with respect to the fixed BH domain dimer) to evaluate the impact of the model used to simulate the SAXS data. For each data set, we ran BUNCH 20 times (BUNCH uses Monte Carlo and simulated annealing and hence can give different models for each run, based on the same data). We found that the impact of the model used for simulating data was small compared with the variations in models obtained using different BUNCH runs. In these models, distance constraints were imposed so that the residues of the PR1 RXXPXXP motif were positioned at the right distance with respect to the residues on SH3 with which they interact in our molecular model ([Figure 1A](#fig1){ref-type="fig"}). Additionally, we augmented the weight of the clash penalty in BUNCH. Using these constraints, BUNCH produced stereochemically plausible solutions where the SH3 domains were positioned either close to (or in contact with) the BH domain of the same molecule (example shown in [Figure 6A](#fig6){ref-type="fig"}) or of the other protomer; [Appendix figure 3A--C](#fig10){ref-type="fig"}). Moreover, the SH3 domains were either positioned towards the N-terminus ([Appendix figure 3A,B](#fig10){ref-type="fig"}), or towards the C-terminus of the BH domains ([Appendix figure 3C](#fig10){ref-type="fig"}). However, the C-terminal positioning of SH3 domains was incompatible with the interaction of GTPases with the BH domain, because the SH3-BH linker region necessarily crossed the GTPase-binding site on BH, and/or the SH3 domains clashed with the GTPase domains. Given that GTPases and PTEN can bind simultaneously, and given that PTEN binding requires the SH3:PR1 interaction, the C-terminal positioning of SH3 domains was not supported by our data. We therefore concluded that the SH3:PR1 interaction is possible within the BH:BH domain dimer framework and that the SH3 domain needs to be located at the N-terminal side of the BH:BH domain dimer.10.7554/eLife.06866.024Appendix figure 3.(Left) distance constraints used in BUNCH.(**A**-**C**) Examples of dimeric SH3-PR1-BH models obtained by BUNCH. SH3: green; SH3-BH linker: magenta; BH dimer: light and dark gray.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.024](10.7554/eLife.06866.024)

B) Molecular model for the PTEN:p85α interaction {#s7-2}
------------------------------------------------

Our experimental analysis showed that PTEN is active when in complex with p85α. Moreover, we showed that this interaction strongly depends on both PR2 and dimeric p85α. This can be explained in two ways: (1) The PTEN:p85α interaction is not a simple peptide:domain interaction between the PR2 peptide and the PTEN phosphatase domain, but also involves direct domain:domain interactions between dimeric p85α SH3-PR1-BH and PTEN. (2) The PTEN:p85α interaction is only a peptide:domain interaction between PR2 and PTEN, and the requirement for dimeric p85α is explained solely by a (flexible) cross-linking of two PTEN molecules. The combined SH3-BH-PR2:PTEN interaction from option 1 appears to be more suitable to explain all phenotypes we observe for the p85α association (protection from WWP2-mediated ubiquitination by outcompeting WWP2, enhanced membrane anchoring, increased phosphatase activity against soluble substrates). However, at this stage, we cannot categorically rule out option 2. We therefore first investigate the more likely option 1 and then evaluate option 2.

### (i) Orientation of PTEN with respect to p85α {#s7-2-1}

In option 1, PTEN association with p85α has to be structurally compatible with the membrane association of PTEN. The surface of PTEN that binds to membranes and the catalytic site that requires binding phospholipid head groups are known ([Appendix figure 4A](#fig11){ref-type="fig"}). Based on this information, we oriented PTEN with respect to the membrane. We then used this PTEN:membrane interaction constraint to place p85α with respect to PTEN. In option 1, the requirement for a p85α dimer is justified by dimeric SH3-PR1-BH-PR2, providing a combined binding surface for PTEN. Given the symmetry of the BH domains and the distance between the PR2 regions, we expect that one PTEN binds to one p85α molecule of the homodimer and that two PTEN molecules bound to the p85α homodimer associate simultaneously with the membrane. Hence, the twofold symmetry axis of the BH dimer has to be perpendicular to the membrane plane. In a model where the p85α dimer is oriented with the SH3 domains towards the membrane, the SH3 domains, even if in close contact with the BH domains, would collide with the membrane and thus block simultaneous interaction of two bound PTEN molecules with the membrane ([Appendix figure 4B](#fig11){ref-type="fig"}). As a consequence, the p85α dimer is most likely oriented with the SH3 domains pointing away from the membrane. Such an orientation would also allow simultaneous binding of GTPases and PTEN to both the p85α dimer and the membrane.10.7554/eLife.06866.025Appendix figure 4.(**A**) approximate positioning of PTEN with respect to the membrane (green).C2 residues required for membrane binding are highlighted. Orange spheres represent a bound L(+)-tartrate molecules found in the PTEN crystal structure (1D5R) and are thought to mimic interactions of PTEN with substrate phosphates([@bib28]). (**B**) When oriented with the SH3 domains (green) pointing towards the membrane, the two PTEN molecules cannot simultaneously interact with the membrane and with PR2.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.025](10.7554/eLife.06866.025)

### (ii) Identifying the most likely p85α binding site on PTEN {#s7-2-2}

To identify the most likely p85α-binding site on PTEN, we applied four criteria: (1) protein--protein interaction sites are normally conserved across species; (2) protein--protein interaction sites are often implicated in crystal packing interactions; (3) PTEN mutations that affect binding to WWP2 should be close or overlapping with the p85α-interacting region on PTEN, because WWP2 and p85α compete for PTEN binding; and (4) a probable protein--ligand interaction site should obtain a significant score in ligand binding site prediction algorithms. [Appendix figure 5](#fig12){ref-type="fig"} shows that these four criteria highlight a similar region on the PTEN phosphatase domain, thus identifying a likely interaction site (encircled in [Appendix figure 5](#fig12){ref-type="fig"}).10.7554/eLife.06866.026Appendix figure 5.(**A**) PTEN is shown in the crystal lattice of 1D5R.Gray: C2; orange: phosphatase; magenta: symmetric molecules. Highly conserved regions are shown as blue spheres. (**B**) Result of Sitehound search (<http://scbx.mssm.edu/sitehound/> ([@bib18]) using a methyl carbon probe). Red and yellow dotted regions are close to the active site and hence unlikely BH interaction regions. (**C**) Maddika et al. have previously observed PTEN mutations that enhance (Y155F; green), slightly enhance (Y138F, red) and slightly decrease (Y174F; blue) WWP2 binding ([@bib32]). Y174 locates to the C2:PTEN interface and is inaccessible to solvent and ligands. Y155 and Y138 both localize to the same side on PTEN and this side is the same as highlighted in (**A**) and (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.06866.026](10.7554/eLife.06866.026)

### (iii) Selection of the most probable interaction model {#s7-2-3}

We used the ClusPro server (<http://cluspro.bu.edu/login.php>) to produce an ensemble of molecular docking models of the BH:PTEN complex based on shape complementarity and interaction surface characteristics. This server was chosen because it produced the best results in the 2013 round of CAPRI (Critical Assessment of Predicted Interactions). Among the 30 best-scored solutions, five solutions clustered and were also compatible with all constraints mentioned above ([Appendix figure 6](#fig13){ref-type="fig"}), including the observation that the C2 domain does not contribute to binding ([Figure 3C](#fig3){ref-type="fig"}).10.7554/eLife.06866.027Appendix figure 6.Cluster of ClusPro models that satisfy all constraints.(**A**) Complexes viewed from the membrane; (**B**) side view with respect to the membrane.**DOI:** [http://dx.doi.org/10.7554/eLife.06866.027](10.7554/eLife.06866.027)

In the docked position, the PTEN phosphatase domain is in proximity of the N-terminal helix--loop--helix fragment of the BH domain, and hence in proximity of both the BH:BH interface and the supposed location of the SH3:PR1 complex. We hypothesize that dimerization is required for either allosterically rearranging the PTEN binding site on the BH domain, or to allow stabilizing interactions between the second BH domain and the flexible 13 N-terminal residues of a PTEN molecule which binds with its phosphatase domain to the first BH domain. The PTEN:p85α interaction also involves PTEN R14, next to K13, a major PTEN ubiquitination site. To test this PTEN:p85α docking model, but also to test interaction option 1 (PTEN binds SH3-PR1-BH in addition to PR2) against option 2 (PTEN only binds PR2 region of p85α), we introduced the triple mutations I127A/I133A/E137A in the BH domain. The observations that this mutation on BH specifically affected PTEN binding, but not p85α dimerization, and that this mutation is synergistic with PR2 mutations support our molecular model ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). More generally, the effect of these mutations supports interaction option 1. The observation that residues within this triple mutant affect PTEN binding eliminates the possibility that one PTEN phosphatase domain binds simultaneously to two BH domains within the dimer, because the dimensions of one PTEN phosphatase domain and the space constraints from the bound GTPase do not allow simultaneous contacts of one PTEN phosphatase domain with PR2, the three mutated residues and the two BH protomers.

### (iv) The suggested p85α-binding site of PTEN is highly mutated in cancer patients {#s7-2-4}

Having observed that cancer patient-derived p85α mutations affect p85α dimerization ([Figure 5](#fig5){ref-type="fig"}), we asked whether patient-derived *PTEN* mutations would also map to the proposed p85α-binding site on PTEN. We therefore searched our in-house endometrial cancer dataset and the *Cancer* Genome Atlas (TCGA) for missense mutations in the PTEN phosphatase domain and mapped these onto the structure model. Out of 62 mutations, 27 localized to the phosphatase surface that is oriented towards the membrane and contains the catalytic site (residues 24, 33--36, 39, 42, 45--47, 92, 93, 165, 167, 171, 123, 125--132, 136, 155, 159; red in [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}); five localized to the C2:phosphatase interface (95, 170, 173, 175, 177; orange); 19 localized to the putative p85α-binding site proposed here (14, 15, 25, 27, 28, 30, 61, 64, 109, 112, 119, 138, 142--145, 148, 152, 153; green), and 11 localized to the opposite side (66, 71, 85, 87, 88, 96, 101, 105, 107, 108, 111; yellow). Hence up to 30% of missense *PTEN* mutations may localize to the putative p85α-binding site.

Conclusions {#s8}
===========

From the data produced by our study and from previously published results, we compiled an ensemble of experimental, computational, structural and functional constraints for the PTEN:p85α interaction. These constraints can be summarized as (1) PTEN binds homodimeric but not monomeric p85α; (2) the dimeric BH:BH structure as observed in the crystal structure and supported by mutational analysis is maintained; (3) SH3:PR1 interactions occur in trans; (4) the PTEN:p85 complex is compatible with binding of Rab and other small GTPases to the p85α BH domain ([Figure 6---figure supplement 1A-B](#fig6s1){ref-type="fig"}); (5) p85α SH3 positioning is compatible with simultaneous GTPase and PTEN binding; (6) p85α interacts with the phosphatase domain of PTEN; (7) the PTEN C2 domain does not contribute to binding; (8) the PTEN:p85α interaction site overlaps with PTEN residues for binding WWP2; (9) p85 homodimers bind unphosphorylated but not phosphorylated PTEN; (10) p85α-bound PTEN remains active, suggesting that the PTEN active sites can bind to membrane-bound PIP~3~; (11) major PTEN ubiquitination sites are protected in the PTEN:p85α interface (K13 and/or K289) ([@bib43]; [@bib14]); (12) p85α mutations at the p85α:PTEN interface weaken PTEN binding, but do not alter p85α homodimerization; and (13) the interface should appear biologically plausible, in terms of the surface covered and the amino acid composition. Finally, the p85α binding site on PTEN is most likely (14) a conserved region of PTEN; (15) a region predicted to be a ligand binding site, and (16) a region that is implicated in PTEN crystal packing interactions. We were able to develop a structural model that satisfies all these constraints ([Figure 6A](#fig6){ref-type="fig"}).

This 'hybrid' model (based on experimental and computational constraints) was corroborated by mutational analysis and correctly predicted cancer patient-derived p85α mutations that disrupt the p85α:PTEN-interacting interface ([Figures 5 and 6](#fig5 fig6){ref-type="fig"}). Our attempt to construct the p85α homodimer and p85α:PTEN structural models herein may therefore allow prediction of the biochemical phenotypes of mutations that occur along the interfaces in the cancer genomes. For a critical evaluation of this model, please see the discussion in the main text.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Regulation of the PI3K Pathway through a p85α Monomer-Homodimer Equilibrium" for consideration at *eLife*. Your article has been favorably evaluated by Tony Hunter (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing Editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This is a carefully performed study that combines biochemical analysis and structural modeling to gain insight into the regulation of PTEN. A major conclusion of the study is the p85 homodimers compete for binding PTEN with the WWP2 E3 ligase. The conclusions of the study are, in general, consistent with the analytical data presented. However, in some instances the conclusions are over-stated and in other instances alternative interpretations of the data are not considered.

1\) [Figure 2A-C](#fig2){ref-type="fig"}. In the subsection headed "Disruption of p85α homodimerization is associated with decreased stability of PTEN through ubiquitination", it is stated that WT p85 decreases and mutant p85 increases ubiquitination. This is true in a relative sense, but it appears that the extent of ubiquitination in each case is decreased compared with the LacZ control. These data should be presented more clearly.

2\) The competition model is compelling, but it appears to be based on over-expression/transfection assays. Studies of endogenous proteins/loss-of-function analysis are needed to provide more convincing support for the authors\' conclusions. For example, does knock-down of WWP2 increase the co-immunoprecipitation of p85 with PTEN (and the reverse experiment).

3\) The interpretation of the transfection assays is limited to the deduction of direct binary interactions between PTEN with p85 homodimers and/or WWP2. Possible roles for signaling changes in the cells transfected with these reagents are not considered. For example, do changes in the PI3K pathway contribute to the changes in the PTEN interactions described? Feed-back or feed-forward signaling mechanisms may play a contributing role.

4\) Are the biochemical interactions described for p85 in this study specific to p85α or does p85β similarly homodimerize and associate with PTEN through the indicated regions? The potential for redundancy in these mechanisms becomes important when one considers the influence of cancer-associated PIK3R1 mutations.

5\) The structural model was constructed through a complicated procedure described in an eight page supplement, which describes some straightforward approaches (e.g. structural homology modeling and/or superposition) and others that are more tenuous (e.g. BUNCH with synthetic SAXS data). The resulting composite model depends on multiple assumptions, with some supporting biochemical/structural constraints, but is nevertheless speculative as the authors acknowledge. A triple mutation on a predicted PTEN-binding surface of the BH domain suggests that a least one of the mutated residues is located in the interface. However, there are no experiments that assess the structure in solution (e.g. actual SAXS experiments). It is difficult to assess the overall likelihood/uniqueness of the model or whether the constraints are sufficient to exclude alternative possibilities. In the absence of direct structural data for the relevant complex, the authors should be more circumspect with respect to the presentation of the speculative model and its implications, including discussion of potential caveats and possible alternative interpretations.

6\) The *K*~*d*~ for dimerization of the SH3-PR1-BH-PR2 fragment of p85α is 10 fold lower than for the full length protein, which is a non-trivial difference. How do the authors explain this result?
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Author response

*This is a carefully performed study that combines biochemical analysis and structural modeling to gain insight into the regulation of PTEN. A major conclusion of the study is the p85 homodimers compete for binding PTEN with the WWP2 E3 ligase. The conclusions of the study are, in general, consistent with the analytical data presented. However, in some instances the conclusions are over-stated and in other instances alternative interpretations of the data are not considered*.

*1)* [*Figure 2A-C*](#fig2){ref-type="fig"}*. In the subsection headed "Disruption of p85α homodimerization is associated with decreased stability of PTEN through ubiquitination", it is stated that WT p85 decreases and mutant p85 increases ubiquitination. This is true in a relative sense, but it appears that the extent of ubiquitination in each case is decreased compared with the LacZ control. These data should be presented more clearly*.

The extent of PTEN ubiquitination in LacZ-transfected cells was higher than in p85α mutant-transfected cells because the amount of PTEN-bound p85α homodimer, which inhibits PTEN ubiquitination, was higher in mutant-transfected cells. The mutants, although they display decreased interaction with PTEN compared with wild-type p85α, were not completely defective in PTEN binding. We have now clarified this in the text (in the first paragraph of the subsection headed "Disruption of p85α homodimerization is associated with decreased stability of PTEN through ubiquitination").

*2) The competition model is compelling, but it appears to be based on over-expression/transfection assays. Studies of endogenous proteins/loss-of-function analysis are needed to provide more convincing support for the authors\' conclusions. For example, does knock-down of WWP2 increase the co-immunoprecipitation of p85 with PTEN (and the reverse experiment)*.

In response to the reviewers' comments, we have performed loss-of function studies using siRNAs that efficiently target WWP-2 or p85α in HEC1A which is an endometrial cancer cell line expressing high levels of WWP-2 and p85α. The interaction between PTEN and p85α, or between PTEN and WWP-2 was increased after knockdown of WWP-2 or p85α respectively. The data are now presented in [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"} and in the text (in the subsection headed "p85α homodimer decreases PTEN binding to the E3 ligase WWP2").

*3) The interpretation of the transfection assays is limited to the deduction of direct binary interactions between PTEN with p85 homodimers and/or WWP2. Possible roles for signaling changes in the cells transfected with these reagents are not considered. For example, do changes in the PI3K pathway contribute to the changes in the PTEN interactions described? Feed-back or feed-forward signaling mechanisms may play a contributing role*.

We agree with the reviewers that it would be interesting to examine whether the PTEN/p85 α/WWP2 interactions are subjected to changes in PI3K pathway signaling, especially through altering feedback and feedforward mechanisms. Negative feedback mediated by S6K ([@bib17]) and positive feedback mediated by mTORC2 ([@bib19]; [@bib39]) have been described in certain cell types and are considered to be the major feedback elements regulating the PI3K pathway. Example of feedforward signaling involves activation of mTOR, in which AKT phosphorylates mTOR directly or indirectly through inactivation of TSC1/TSC2 ([@bib15]; [@bib42]).

To investigate whether these regulatory mechanisms could affect the interaction of PTEN with p85α or WWP2 when these molecules are altered by transfection, we suppressed S6K or mTORC2 signaling using S6K or Rictor siRNA, respectively, and rapamycin was used to inhibit mTORC1 activity in the cell line used in this study (KLE). In addition, we also targeted AKT activity using the specific AKT inhibitor MK2206. S6K siRNA increased AKT phosphorylation implicating the existence of negative feedback in KLE cells. In contrast to the suggested role in mediating a positive feedback at least in some cell lines, Rictor siRNA did not decrease phosphorylated AKT in the KLE cell line, although the siRNA decreased Rictor expression by 80%. Importantly, both S6K and Rictor siRNA had no effect on PTEN interactions with p85α or WWP2. Rapamycin and MK2206, which efficiently inhibited mTOR and AKT phosphorylation, respectively, also had no effect on these PTEN interactions with p85α or WWP. Thus, inhibition of these feedback and feedforward loops, and inhibition of different nodes of the PI3K pathway, does not affect the degree of PTEN association with p85α or WWP2, suggesting that the PTEN interactions with p85α or WWP2 are unlikely to be explained by mutant-triggered changes in PI3K downstream signaling or regulatory loops. These data and discussion are now added in [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"} and in the text (in the subsections headed "Disruption of p85α homodimerization is associated with decreased stability of PTEN through ubiquitination" and "p85α homodimer decreases PTEN binding to the E3 ligase WWP2").

*4) Are the biochemical interactions described for p85 in this study specific to p85α or does p85β similarly homodimerize and associate with PTEN through the indicated regions? The potential for redundancy in these mechanisms becomes important when one considers the influence of cancer-associated PIK3R1 mutations*.

The extent of functional redundancy between p85α and p85β is an interesting area of investigation. Harpur et al. have reported the homodimer formation of recombinant p85β proteins using size exclusion chromatography ([@bib16]). To further assess the reviewers\' question, we used immunoprecipitation assays and observed that p85β homodimerized and interacted with PTEN but the interactions were much weaker than observed for p85α. Further, in contrast to wild type p85α, p85β did not stabilize PTEN (data are now added in [Figure 1--figure supplement 5A and 5C](#fig1s5){ref-type="fig"}).

The nSH2-iSH2-cSH2 fragment that binds p110 is 80% identical in sequence between p85α and p85β. In contrast, p85α and p85β share only 30% protein sequence identity between their BH domains that are critical for PTEN binding. Importantly, the BH region that mediates dimerization in p85α is not conserved in p85β, neither in sequence nor in structure (the structure of the p85β BH domain has been deposited in the PDB, accession number 2XS6, but no associated manuscript has been published to date). Accordingly, the BH domain dimer centered on M176 present in the p85α crystal is not present in the crystal lattice of p85β BH (see [Figure 1--figure supplement 5B](#fig1s5){ref-type="fig"}). Instead, the p85β BH domain crystals contain another symmetric domain-domain interface. Therefore if the p85β BH domain contributes to stabilizing p85β homodimers, then it would do this using a different dimerization interface than p85α BH. Given that the dimeric structure of p85α BH domain is important for both PTEN binding and stabilization, these data explain our experimental observation of weak PTEN binding and lack of PTEN stabilization by p85β. Additional experiments, structure figure and discussion are now included in [Figure 1--figure supplement 5](#fig1s5){ref-type="fig"} and in the text (in the subsection headed "The p85α BH:BH domain interaction contributes to stabilization of the p85α homodimer").

*5) The structural model was constructed through a complicated procedure described in an eight page supplement, which describes some straightforward approaches (e.g. structural homology modeling and/or superposition) and others that are more tenuous (e.g. BUNCH with synthetic SAXS data). The resulting composite model depends on multiple assumptions, with some supporting biochemical/structural constraints, but is nevertheless speculative as the authors acknowledge. A triple mutation on a predicted PTEN-binding surface of the BH domain suggests that a least one of the mutated residues is located in the interface. However, there are no experiments that assess the structure in solution (e.g. actual SAXS experiments). It is difficult to assess the overall likelihood/uniqueness of the model or whether the constraints are sufficient to exclude alternative possibilities. In the absence of direct structural data for the relevant complex, the authors should be more circumspect with respect to the presentation of the speculative model and its implications, including discussion of potential caveats and possible alternative interpretations*.

Importantly, the hypothetical model presented is not used as a proof for our conclusions or indeed as a stand-alone model to explain the interactions between p85α monomers or between p85α and PTEN or WWP2, but to rather to guide and inform the experiments to be performed to elucidate the functional role of particular residues in p85α. We had emphasized this in the text and now clarify this further (e.g. in the Results, we state: "We used this structural information to build a theoretical homology model for the SH3:PR1 interaction to guide studies aimed at identifying the amino acids involved in the molecular interactions". In the Discussion, we added the following: "while currently representing a useful working model for guiding and informing experimental analysis, our theoretical PTEN:p85α structure requires confirmation by an experimental structure". [Appendix 1](#app1){ref-type="app"} also provides further clarification on this point). Indeed, the predictive power and agreement of the model with the experimental mutation analysis support the utility of the molecular modeling.

Of course, in absence of an experimental 3D structural model, our complex structure remains hypothetical, and we cannot formally exclude other structural complexes that could satisfy our constraints, or that some of the constraints are wrong. As requested, we have now included a more critical discussion of the model and described its possible shortcomings (Discussion). To be more circumspect with respect to the presentation of the speculative model, we have limited its presentation in the manuscript from three to only one figure (the original [Figures 6A-C](#fig6){ref-type="fig"} have been reduced to the revised [Figure 6A](#fig6){ref-type="fig"}). Additionally, to avoid risks of over-interpretation by the reader, we have now decreased the level of resolution of this figure, making it very schematic and cartoon-like in appearance.

*6) The* K~d~ *for dimerization of the SH3-PR1-BH-PR2 fragment of p85α is 10 fold lower than for the full length protein, which is a non-trivial difference. How do the authors explain this result*?

Indeed, the shorter N-terminal fragment consistently displayed a ten-fold lower dimerization *K*~*d*~ than the full-length protein. These differences are reproducible and significant. In AUC, these differences are also robust with respect to the model used for fitting, and the type of data acquisition (sedimentation equilibrium or velocity). Determination of the molecular basis of this observation would require complete experimental determination of structures of dimeric and monomeric p85 α (full-length and fragments thereof). Such structural analysis is non-trivial because of the size and flexibility of this multi-domain protein, and hence is beyond the scope of our manuscript.

Nonetheless, we speculate that the mildly inhibitory nature of the C-terminal nSH2-iSH2-cSH2 fragment arises from additional entropic penalty upon full-length dimerization, and/or from weak intramolecular interactions occurring between the SH3-BH fragment and the nSH2 -iSH2-cSH2 fragment in the monomer, which have to be displaced upon dimerization. This possibility has now been included in the Results section ("The difference in dimerization *K*~*d*~ between the N-terminal fragment and full-length p85α might indicate an additional entropic penalty arising upon full-length dimerization...").
